CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming scientific and investor conferences. The presentation details are as follows:

• 16^th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 3:00 p.m. ET at the Waldorf Astoria in New York City, NY
• Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014 at 1:25 p.m. ET at the Waldorf Astoria in New York City, NY
• 21^stInternational Molecular Medicine Tri-Conference on Thursday, February 13 through Friday, February 14, 2014 at the Westin St. Francis in San Francisco, CA

Symposium: Targeting Cancer Stem Cells: New Opportunities for Oncology Therapeutics – Day 1
Presentation: Chair of session - Preclinical Advances Targeting Cancer Stem Cells
Date and Time: Thursday, February 13, 2014 at 1:50 p.m. PT

Symposium: Targeting Cancer Stem Cells: New Opportunities for Oncology Therapeutics – Day 2
Presentation: Strategies to Develop Agents that Preferentially Target Cancer Stem Cells: Clinical Candidates Targeting FAK and PI3K/mTOR
Date and Time: Friday, February 14, 2014 at 8:00 a.m. PT

Webcasts of the BIO CEO and Leerink Swann presentations can be accessed by visiting the investors section of the Company’s website at www.verastem.com. Replays of each of the webcasts will be archived on the Verastem website for 90 days following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com